322 related articles for article (PubMed ID: 17659577)
1. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA; García-García JA; Aguilar-Guisado M; Ríos-Villegas MJ; Ruiz-Morales J; Rivero A; del Valle J; Luque R; Rodríguez-Baño J; González-Serrano M; Camacho A; Macías J; Grilo I; Gómez-Mateos JM;
Hepatology; 2007 Sep; 46(3):622-30. PubMed ID: 17659577
[TBL] [Abstract][Full Text] [Related]
2. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.
Pineda JA; Aguilar-Guisado M; Rivero A; Girón-González JA; Ruiz-Morales J; Merino D; Ríos-Villegas MJ; Macías J; López-Cortés LF; Camacho A; Merchante N; Del Valle J;
Clin Infect Dis; 2009 Oct; 49(8):1274-82. PubMed ID: 19772387
[TBL] [Abstract][Full Text] [Related]
3. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Martinez-Sierra C; Arizcorreta A; Díaz F; Roldán R; Martín-Herrera L; Pérez-Guzmán E; Girón-González JA
Clin Infect Dis; 2003 Feb; 36(4):491-8. PubMed ID: 12567308
[TBL] [Abstract][Full Text] [Related]
4. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use.
Connoy A; Turner J; Núñez M
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):719-25. PubMed ID: 21128862
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J;
Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
[TBL] [Abstract][Full Text] [Related]
6. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
[TBL] [Abstract][Full Text] [Related]
7. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
[TBL] [Abstract][Full Text] [Related]
9. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease.
Neff GW; Bonham A; Tzakis AG; Ragni M; Jayaweera D; Schiff ER; Shakil O; Fung JJ
Liver Transpl; 2003 Mar; 9(3):239-47. PubMed ID: 12619020
[TBL] [Abstract][Full Text] [Related]
10. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
[TBL] [Abstract][Full Text] [Related]
11. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.
Torre D; Tambini R; Cadario F; Barbarini G; Moroni M; Basilico C
Clin Infect Dis; 2001 Nov; 33(9):1579-85. PubMed ID: 11588701
[TBL] [Abstract][Full Text] [Related]
12. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
[TBL] [Abstract][Full Text] [Related]
14. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
[TBL] [Abstract][Full Text] [Related]
15. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
17. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
Pineda JA; Macías J
J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
[TBL] [Abstract][Full Text] [Related]
18. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
[TBL] [Abstract][Full Text] [Related]
19. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; Soriano V
AIDS; 2013 Apr; 27(7):1129-34. PubMed ID: 23276803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]